A lawsuit was filed on behalf of investors in Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares over alleged securities laws violations.

San Diego, CA -- (SBWire) -- 02/10/2021 --An investor, who purchased NASDAQ: VYGR shares, filed a lawsuit against Voyager Therapeutics, Inc over alleged violations of Federal Securities Laws.

Investors who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) have certain options and for certain investors are short and strict deadlines running. Deadline: March 24, 2021. Voyager Therapeutics, Inc. (NASDAQ: VYGR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cambridge, MA based Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. Included in the Company's preclinical programs is VY-HTT01 for Huntington's Disease. Voyager Therapeutics, Inc represent that VY-HTT01 is intended to work by knocking down HTT expression in neurons and astrocytes in the striatum and cortex (discrete regions in the brain that can be targeted with adeno-associated virus ("AAV") gene therapy delivered directly into the brain), thereby reducing the level of toxicity associated with mutated protein in these brain regions, and slowing the progression of cognitive and motor symptoms.

On October 12, 2020, Voyager Therapeutics, Inc. disclosed that it "has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington's disease." Specifically, Voyager advised investors that it "has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters."

Shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) declined on October 13, 2020 to $10.90 per share.

Then, on November 9, 2020, Voyager Therapeutics, Inc announced the Company's third quarter 2020 financial results and corporate updates. In the announcement, Voyager Therapeutics, Inc disclosed that, with respect to its IND application for VY-HTT01, "Voyager recently received written feedback from the FDA requesting additional information on specific CMC topics, including drug-device compatibility and drug substance and product characterization."

The plaintiff claims that between June 1, 2017 and November 9, 2020, the defendants made false and/or misleading statements and failed to disclose to investors that the Company's VY-HTT01 IND submission to the FDA lacked key information regarding certain chemistry, manufacturing and controls ("CMC") matters, including, inter alia, drug-device compatibility and drug substance and product characterization, that the Company's IND submission for VY-HTT01 was therefore deficient, that the Company had thus materially overstated the likelihood of FDA approval for VY-HTT01 based on the IND submission, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.